Skip to main content

Agora
Sign in

Senate bill · S. 1302 (119th Congress)

Increasing Transparency in Generic Drug Applications Act

U.S. Senate

Latest action Apr 3, 2025

Sponsor: Margaret Wood Hassan (U.S. Senator for New Hampshire, Democratic)

Follow

Following needs an Agora account. You will sign in first, then come back to this page.

From Congress.gov and official rosters. This record was last updated Jul 30, 2026. About our data

Summary

Would amend federal drug law to let a person submitting a generic drug application request information from the FDA about whether laboratory (in vitro) testing may be used to demonstrate that a generic drug works the same as its brand-name counterpart when the two share the same inactive ingredients.

AI summary. Not an official summary. How we handle summaries

Where it stands

Assigned to a committee for review.

  1. Introduced
  2. In committee
  3. Up for a vote
  4. Passed one chamber
  5. Passed
  6. Enacted

Committee

Senate Committee on Health, Education, Labor, and Pensions · U.S. Senate

Your position on this bill

Choose the position closest to yours. You'll sign in or create an account to save it.

Sign in or create an account to give your position

Cosponsors

6

Cosponsors listed on Congress.gov, shown A to Z.

  • Republican4
  • Democratic2

This bill has cosponsors from more than one party.

Shown in neutral colors by design; Agora is non-partisan.

Related bills

As identified by Congress.gov.

Full history

  1. Apr 3, 2025

    Introduced

    Introduced in U.S. Senate

    U.S. Senate

  2. Apr 3, 2025

    Referred to committee

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

  3. Apr 3, 2025

    Referred to committee

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

  4. Apr 3, 2025

    Referred to committee

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Read the record